mProX™ Human RARG Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Nuclear Receptor
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Carol
Verified Customer
Kevin
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 The expression levels of RARγ and E-cadherin in HCC cell lines.
RT-PCR was used to assess RARγ and E-cadherin expression in the designated cell lines. The mRNA levels of E-cadherin and RARγ in HCC cell lines are correlated using dot plots. The dotted line illustrates the inverse relationship between E-cadherin and RARγ at the mRNA levels.
Ref: Gan, Wen-Juan, et al. "RARγ-induced E-cadherin downregulation promotes hepatocellular carcinoma invasion and metastasis." Journal of Experimental & Clinical Cancer Research 35.1 (2016): 1-11.
Pubmed: 27756432
DOI: 10.1186/s13046-016-0441-9
Research Highlights
More than 50% of juvenile cancer treatment protocols include anthracyclines; nevertheless, anthracycline-induced cardiotoxicity (ACT) limits the clinical use of anthracyclines by causing asymptomatic cardiac dysfunction and congestive heart failure in up to 57% and 16% of patients, respectively.
Aminkeng, Folefac, et al. "A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer." Nature genetics 47.9 (2015): 1079-1084.
Pubmed:
26237429
DOI:
10.1038/ng.3374
Within the nuclear receptor superfamily, retinoic acid receptor α (RARα) and retinoic acid receptor β (RARβ) are 90% homologous with retinoic acid receptor γ (RARγ). Although acute promyelocytic leukemia (APL) is known to be associated with RARA rearrangements, RARG rearrangements can also mimic this type of leukemia.
Conserva, Maria Rosa, et al. "RARG gene dysregulation in acute myeloid leukemia." Frontiers in Molecular Biosciences 6 (2019): 114.
Pubmed:
31709264
DOI:
10.3389/fmolb.2019.00114